Conference Coverage

Colorectal cancer treatment outcomes in older adults


 

FROM ASCO GI 2023

The challenges of treating older patients

If and how older patients with colorectal cancer should be treated is not clear cut. While 20% of patients in the United States who have colorectal cancer are over 80 years old, each case should be evaluated individually, experts say.

Writing in a 2015 review of colorectal cancer treatment in older adults, Monica Millan, MD, PhD, of Joan XXIII University Hospital, Tarragona, Spain, and colleagues, wrote that physiological heterogeneity and coexisting medical conditions make treating older patients with colorectal cancer challenging.

“Age in itself should not be an exclusion criterion for radical treatment, but there will be many elderly patients that will not tolerate or respond well to standard therapies. These patients need to be properly assessed before proposing treatment, and a tailored, individualized approach should be offered in a multidisciplinary setting,” wrote Dr. Millan, who is a colorectal surgeon.

The authors suggest that older patients who are fit could be treated similarly to younger patients, but there remain uncertainties about how to proceed in frail older adults with comorbidities.

“Most elderly patients with cancer will have priorities besides simply prolonging their lives. Surveys have found that their top concerns include avoiding suffering, strengthening relationships with family and friends, being mentally aware, not being a burden on others, and achieving a sense that their life is complete. The treatment plan should be comprehensive: cancer-specific treatment, symptom-specific treatment, supportive treatment modalities, and end-of-life care,” they wrote.

The U.S. Preventive Services Task Force recommends colorectal cancer screening for men and women who are between 45 and 75 years old; however, screening for patients between 76 and 85 years old should be done on a case-by-case basis based on a patient’s overall health, screening history, and the patient’s preferences.

Colorectal cancer incidence rates have been declining since the mid-1980s because of an increase in screening among adults 50 years and older, according to the American Cancer Society. Likewise, mortality rates have dropped from 29.2% in 1970 to 12.6% in 2020 – mostly because of screening.

Dr. Shimomura has no relevant financial disclosures.

The Gastrointestinal Cancers Symposium is sponsored by the American Gastroenterological Association, the American Society for Clinical Oncology, the American Society for Radiation Oncology, and the Society of Surgical Oncology.

Pages

Recommended Reading

3D-printed tumor models could advance new cancer therapies
MDedge Hematology and Oncology
Does appendectomy raise the risk for colorectal cancer?
MDedge Hematology and Oncology
Palliative radiotherapy successfully reduces end-stage liver cancer pain
MDedge Hematology and Oncology
Canadian guidance recommends reducing alcohol consumption
MDedge Hematology and Oncology
Regorafenib: New option for advanced gastroesophageal cancer?
MDedge Hematology and Oncology
Adding SBRT to sorafenib boosts survival in liver cancer
MDedge Hematology and Oncology
SUNLIGHT shows new standard of care in refractory metastatic CRC
MDedge Hematology and Oncology
New ‘reference regimen’ in metastatic pancreatic cancer?
MDedge Hematology and Oncology
Physician group issues 31 treatment recommendations for early-onset colorectal cancer
MDedge Hematology and Oncology
Immunotherapy with antibiotics doesn’t worsen biliary tract cancer outcomes
MDedge Hematology and Oncology